Electra Therapeutics

Electra Therapeutics is a clinical-stage biotechnology company developing therapies that target novel mechanisms in immunology and cancer. Its lead candidate, ELA026, is a monoclonal antibody designed to treat severe inflammatory disorders characterized by abnormal myeloid cell and T lymphocyte activity. ELA026 enables rapid, potent, and selective depletion of these circulating immune cells that drive inflammation, while preserving the normal CD47/SIRPα immune checkpoint function. The program is currently in pivotal development for secondary hemophagocytic lymphohistiocytosis (sHLH)a life-threatening disease often associated with underlying malignancies and for which no approved treatments currently exist.